Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17438421 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAATSHRNAAACPB1 | |
| SCHEMBL15748998 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAATSHRNAAACPB1 | |
| SCHEMBL19015180 | 1.00 | ALDH1A1 (0.56) | ALDH1A1GAATSHRNAAACPB1 | |
| Hydrochloric Acid SCHEMBL29890850 | 0.98 | ALDH1A1 (0.55) | ALDH1A1GAATSHRNAAACPB1 | |
| Hydrochloric Acid SCHEMBL29891152 | 0.98 | ALDH1A1 (0.55) | ALDH1A1GAATSHRNAAACPB1 | |
| SCHEMBL30260013 | 0.87 | ALDH1A1 (0.56) | ALDH1A1GAATSHRNAAACPB1 | |
| SCHEMBL1006562 | 0.86 | ALDH1A1 (0.65) | ALDH1A1GAATSHRNAAACPB1 | |
| SCHEMBL21653774 | 0.85 | ALDH1A1 (0.45) | ALDH1A1GAATSHRNAAACPB1 | |
| Hydrochloric Acid SCHEMBL25328114 | 0.85 | ALDH1A1 (0.63) | ALDH1A1GAATSHRNAAACPB1 | |
| SCHEMBL8094832 | 0.84 | HTR2C (0.47) | ALDH1A1GAATSHRNAAACPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368192-A1 | Nitrogen-Containing Heterocyclic Compound, and Preparation Method Therefor, Intermediate Thereof, and Application Thereof | SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4365178-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | Shanghai Allist Pharmaceuticals Co., Ltd. (CN) | 2024-05-08 | — | — | EP | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| WO-2022022364-A1 | PYRROLIDINE INTEGRIN MODULATOR AND USE THEREOF | 清药同创(北京)药物研发中心有限公司 | 2022-02-03 | — | — | WO | disclosed |
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | ALDH1A1 3733/4885GAA 405/4885TSHR 3953/4885 |
| US-20240368192-A1 | Nitrogen-Containing Heterocyclic Compound, and Preparation Method Therefor, Intermediate Thereof, and Application Thereof | KRAS, NRAS, HRAS | ALDH1A1 2187/4885GAA 3006/4885TSHR 4716/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | ALDH1A1 3733/4885GAA 405/4885TSHR 3953/4885 |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | ALDH1A1 3324/4885GAA 2393/4885TSHR 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.